Kisspeptin-10
The master upstream trigger of the reproductive axis — a hypothalamic neuropeptide that ignites GnRH release and the entire LH/FSH/testosterone cascade.
Kisspeptin-10 is the 10-amino-acid C-terminal fragment of kisspeptin, the KISS1 gene product that sits at the very top of the hypothalamic-pituitary-gonadal (HPG) axis. By binding the KISS1R (GPR54) receptor on GnRH neurons, it drives pulsatile GnRH release and the downstream LH, FSH, and gonadal steroid cascade. It is under active Phase 1/2 clinical investigation for fertility, ovulation induction in IVF, hypogonadism, and hypoactive sexual desire disorder, but it is not FDA-approved for any indication and remains a research-only compound.
Class
Endogenous neuropeptide fragment (KISS1R/GPR54 agonist)
Half-life
~4 minutes in plasma (KP-10); the full-length KP-54 parent runs ~29-30 minutes. Some vendor pages list ~27-28 minutes for KP-10.
Routes
Subcutaneous, Intravenous (clinical research)
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Activates the entire HPG axis from the top
As the obligate upstream driver of pulsatile GnRH release, kisspeptin-10 stimulates GnRH neurons to fire, producing downstream LH and FSH secretion and gonadal steroidogenesis. Human infusion studies show sustained LH pulse generation across healthy, hypogonadal, and PCOS subjects without receptor desensitization over 22 hours.
Testosterone and spermatogenesis support
In men, kisspeptin-driven LH/FSH restoration stimulates Leydig cell testosterone production and Sertoli cell spermatogenesis. Continuous infusion has been reported to raise testosterone from roughly 16.6 to 24.0 nmol/L, making it a research tool for hypogonadotropic hypogonadism and post-suppression axis recovery.
Ovulation triggering with lower OHSS risk
In IVF research, kisspeptin (chiefly the KP-54 form) can trigger oocyte maturation as an alternative to hCG, producing roughly 3x smaller ovarian volumes and dramatically reducing ovarian hyperstimulation syndrome risk. A Phase 2 trial (Abbara et al., NEJM 2020) supported this as a clinically relevant alternative trigger for high-risk patients.
Central effects on sexual desire
Kisspeptin receptors in limbic structures (amygdala, hippocampus, cingulate cortex) mediate effects on arousal that appear separable from its hormonal actions. Double-blind crossover trials at Imperial College reported ~56% greater penile tumescence in men with HSDD and fMRI changes in sexual-processing brain regions in women.
Mood and anxiety modulation
Limbic KISS1R signaling has been linked to attenuated activity in negative-mood and anxiety regions; a 2025 study confirmed kisspeptin stimulates reproductive hormones without provoking anxiety. Evidence here is preliminary and not a clinical indication.
Non-suppressive alternative to hCG or SERMs
Because it acts at the hypothalamus rather than at the estrogen receptor or gonad directly, kisspeptin is explored off-label as a physiologically complete option for HPG axis recovery after androgen or TRT suppression, without the LH-receptor desensitization of hCG or the side-effect profile of SERMs.
Mechanism
How it works
Kisspeptin-10 signals through a single G-protein-coupled receptor, KISS1R (formerly GPR54), expressed prominently on GnRH neurons in the hypothalamus and at lower levels in the placenta, gonads, and limbic reward circuitry. KISS1R activation couples predominantly to Gαq/11, activating phospholipase C, generating IP3 and DAG, raising intracellular calcium, and triggering GnRH release from neuron terminals in the median eminence. Kisspeptin is currently understood to be the obligate upstream driver of pulsatile GnRH release: the GnRH neurons set pulse timing, but kisspeptin input controls whether and how strongly they fire.
Under physiology, kisspeptin (KNDy) neurons in the arcuate nucleus fire synchronously to generate GnRH pulses, while kisspeptin neurons in the preoptic/AVPV area drive the mid-cycle LH surge in females. GnRH released into the hypophyseal portal circulation stimulates pituitary gonadotrophs to secrete LH and FSH; LH drives gonadal testosterone or estrogen and ovulation, while FSH drives spermatogenesis and follicular development. The full cascade — KP-10 → GnRH → LH/FSH → gonadal steroids → gametogenesis — takes roughly 20–60 minutes from a subcutaneous or IV dose to a measurable gonadotropin rise.
KP-10 is a high-affinity full agonist at KISS1R with low-nanomolar potency and essentially no cross-reactivity with other GPCRs. Signaling appears biased toward Gαq over β-arrestin recruitment, which may explain its relatively favorable desensitization profile compared with GnRH analogs — pulsatile or intermittent dosing maintains responsiveness, though continuous high-dose exposure can eventually downregulate the axis. Its plasma half-life is extremely short (~4 minutes) due to rapid peptidase degradation, yet the downstream LH/FSH response lasts 1–2 hours because gonadotrophs need time to transcribe and secrete the hormones. This is why kisspeptin is given either as continuous infusion or as frequent boluses.
Beyond the reproductive axis, KISS1R expression in limbic structures mediates kisspeptin's effects on sexual desire, emotional processing, and mood; direct receptor expression on ovarian theca/granulosa and testicular Leydig cells may locally modulate steroidogenesis; and trophoblast-derived kisspeptin regulates placental development, explaining the large rise in plasma kisspeptin during pregnancy. Longer-acting forms exist — KP-54 (half-life ~30 min) and engineered analogs such as MVT-602 (Myovant Sciences, ~60–90 min half-life) — but plain KP-10 remains the most accessible research form.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
A 5 mg KP-10 vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL. On a U-100 insulin syringe: 1 unit (0.01 mL) = 25 mcg, 4 units = 100 mcg, 10 units = 250 mcg, 20 units = 500 mcg. Alternative dilutions: 5 mg + 1 mL = 5 mg/mL (1 unit = 50 mcg, cleaner at higher doses); 5 mg + 5 mL = 1 mg/mL (1 unit = 10 mcg, for fine titration). Dribble BAC water down the vial wall, swirl gently (do not shake), refrigerate immediately.
Beginner — Axis Recovery Support
- Dose
- 100 mcg per dose
- Frequency
- Twice daily (morning and evening), tapering to once daily in weeks 5-8
- Timing
- ~12 hours apart
- Duration
- 8 weeks (weeks 1-4 twice daily, weeks 5-8 once daily)
- Route
- Subcutaneous
Most common off-label use, for men in post-cycle or TRT-break recovery. Usually combined with hCG and/or a SERM rather than used alone. Because plasma half-life is ~4 min, twice-daily dosing gives pulsatile stimulation, not continuous drive. Assess LH, FSH, total/free testosterone, and estradiol at 4 and 8 weeks.
Beginner — Sexual Desire / HSDD Exploration
- Dose
- 100-200 mcg per dose
- Frequency
- On-demand rather than scheduled
- Timing
- 30-90 minutes before the desired effect window
- Duration
- Acute / as-needed (not a chronic daily regimen)
- Route
- Subcutaneous
For kisspeptin's central libido effects. May be repeated daily during an active interest phase without significant tolerance; subjective benefit often builds over 2-4 weeks of regular use. Acute effects (libido, genital sensitivity, emotional engagement) appear within 1-2 hours.
Intermediate — Higher-Dose or Pulsatile
- Dose
- 200-500 mcg twice daily; or 50-100 mcg every 90-120 minutes for pulsatile drive
- Frequency
- Twice daily, or up to 8-10 micro-injections/day for pulsatile mimicry
- Timing
- 12-hour interval, or every 90-120 min during waking hours
- Duration
- Short intensive 'kickstart' periods for pulsatile; 8-12 week blocks for twice-daily
- Route
- Subcutaneous
For users who completed a beginner cycle and want stronger axis drive. LH/FSH dose-response plateaus around 500-1000 mcg — higher doses add side-effect risk without additional drive. Pulsatile every-90-min dosing is the most physiological but practically difficult outside infusion-pump research.
Advanced — Prolonged / Clinical Context
- Dose
- 200-500 mcg twice daily (prolonged); clinical HSDD research uses ~1 nmol/kg/h IV infusion
- Frequency
- Twice daily for 2-3 months in refractory cases; continuous IV in clinical settings
- Timing
- Physician/endocrinology guided
- Duration
- 2-3 months for long-standing suppression, 6-12 weeks for functional hypogonadism
- Route
- Subcutaneous or IV (research)
For experienced users with specific clinical contexts, ideally alongside an endocrinology-literate physician. Chronically suppressed axes may need longer sustained stimulation; sequential gonadorelin-then-KP-10 strategies and GnRH stimulation testing help distinguish hypothalamic from pituitary suppression. Not first-line for age-related hypogonadism.
Clinical — Ovulation Induction (KP-54, medical only)
- Dose
- 9.6 nmol/kg IV single trigger dose (roughly 50-100 mcg/kg for most women)
- Frequency
- Single trigger dose replacing hCG
- Timing
- Timed to oocyte maturation under monitoring
- Duration
- Single administration per IVF cycle
- Route
- Intravenous
Uses KP-54, not KP-10, and must be performed only under reproductive-endocrinology supervision with ultrasound and lab monitoring. Self-administered kisspeptin for ovulation induction is strongly discouraged.
- The clinical dose ranges in research: axis recovery 100-500 mcg SC twice daily; on-demand desire dosing 100-200 mcg SC 60-90 min before activity; HSDD trials ~1 nmol/kg/h (~4-8 mcg/kg/h) IV; ovulation induction (KP-54) 9.6 nmol/kg IV.
- Doses above ~1 mg per injection produce no additional axis drive in published dose-response studies and only add side-effect risk — stay within 100-500 mcg per dose for most off-label use.
- KP-10 will NOT work during active high-dose androgen administration — exogenous androgen negative feedback overwhelms any upstream stimulation. It is relevant during recovery phases (typically 2-4 weeks post-cycle), not during active suppression.
- Effects for axis recovery are measured in lab trends over weeks, not acute sensations. LH/FSH rises within days, testosterone follows over 2-4 weeks, full normalization often 6-12 weeks.
- Use contraception during active use — kisspeptin can induce ovulation and raise fertility potential.
- Lyophilized KP-10 is stable refrigerated/frozen for 12-24 months; reconstituted solution is stable refrigerated (2-8°C) for ~3-4 weeks. Do not freeze reconstituted peptide; discard if cloudy or discolored.
- When switching between KP-10 and KP-54 preparations, dose in equivalent molar amounts rather than by mass, since KP-54 has a higher molecular weight.
Evidence
Research & clinical studies (9)
The roles of kisspeptin and neurokinin B in GnRH pulse generation in humans, and their potential clinical application
Continuous kisspeptin-10 infusion at receptor-saturating levels increased LH (GnRH) pulse frequency across healthy volunteers, hypogonadal subjects, PCOS, and NKB-pathway mutations without receptor desensitization over 22 hours, establishing it as a potent, sustained HPG-axis activator.
PMID 34962670Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome
In a randomized trial of 15 women with PCOS, a 7-day NK3 receptor antagonist course reduced LH pulse frequency (0.5 vs 0.8 pulses/h), demonstrating the kisspeptin/neurokinin B interplay in gonadotropin control.
Can kisspeptin be a new treatment for sexual dysfunction?
Summarizes evidence that kisspeptin activates the HPG axis and neural circuits governing sexual behavior, with human studies linking it to increased brain activity in sexual and emotional processing regions, positioning it as a candidate therapeutic for disorders of sexual desire.
PMID 40189467Phase-dependent changes in serum kisspeptin and irisin levels across the menstrual cycle in healthy women
In 21 healthy premenopausal women, serum kisspeptin was lowest during menses and peaked in the luteal phase, with a positive correlation with irisin in the follicular phase, documenting physiological kisspeptin fluctuation across the cycle.
PMID 41042501Kisspeptin-10 attenuates pulmonary arterial hypertension via restoration of mitochondrial function in pulmonary artery smooth muscle cells
Kisspeptin-10, acting through GPR54, significantly reduced pulmonary arterial hypertension in a mouse model by restoring mitochondrial function and reducing excessive mitophagy in pulmonary artery smooth muscle cells.
PMID 41955717The KISS1/KISS1R Axis in Human Placentation: Molecular Mechanisms and Implications for Foetal Growth Restriction and Pre-Eclampsia
KP-10 signaling through KISS1R regulates placental development and vascular adaptation; reduced maternal kisspeptin is associated with fetal growth restriction and pre-eclampsia, marking KISS1/KISS1R dysregulation as an early placental disturbance.
PMID 42123334Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures
Kisspeptin-10 increased glycosaminoglycan and decorin content in human cardiac fibroblast cultures via GPR54 activation and FAK signaling, suggesting a role in cardiac extracellular matrix remodeling.
PMID 42159865Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory axis
Exogenous kisspeptin-10 suppressed ovarian cancer progression by targeting the SP1-hTERT-ZEB1 regulatory axis, consistent with the peptide family's original metastasis-suppressor role.
PMID 42292313Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices
Developed and validated an analytical workflow for detecting peptidic and non-peptidic doping agents, including kisspeptin-10, in dried and liquid blood matrices.
PMID 42328738Combinations
Stacking & blends
PT-141 + Kisspeptin-10 (Sexual Health)
Central and upstream sexual function support
Combines PT-141's direct melanocortin (MC4R) receptor activation for arousal with kisspeptin-10's hypothalamic HPG-axis stimulation. PT-141 enhances desire and performance at the CNS level independent of vascular mechanisms, while kisspeptin drives pulsatile LH/GnRH release to support the hormonal underpinning of libido — targeting sexual function at two different levels of the neuroendocrine hierarchy.
KP-10 + hCG + Enclomiphene (Post-Cycle Triple Stack)
Comprehensive HPG axis recovery after androgen suppression
Targets three levels of the axis simultaneously: KP-10 stimulates the hypothalamus, enclomiphene blocks estrogen negative feedback at the pituitary, and hCG acts directly at testicular LH receptors. Typically run 8-12 weeks then reassessed with labs.
KP-10 + Gonadorelin (Sequential Axis Restart)
Restore pituitary then hypothalamic drive in refractory suppression
Gonadorelin (GnRH) pulses restore pituitary responsiveness for 4-6 weeks, followed by KP-10 to restore hypothalamic drive. Listed as a synergistic/compatible pairing since the two act at different levels of the axis.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Hormone-sensitive cancers (prostate, hormone-receptor-positive breast, endometrial)
- Pregnancy and breastfeeding (outside supervised ovulation-induction protocols)
- Active pituitary tumor or prolactinoma
- Known hypersensitivity to kisspeptin preparations
- Caution during active major depressive episodes (limited data)
Phase 1/2 trials at Imperial College report an excellent short-term safety profile with no serious adverse events; the most common effect is transient flushing. Because kisspeptin drives endogenous sex-steroid production, it is contraindicated in hormone-sensitive malignancies. Concerns center on over-stimulation of the axis and unintended fertility rather than direct toxicity; long-term safety of repeated dosing has not been established. Use contraception during active use, as kisspeptin can induce ovulation.
FAQ
Kisspeptin-10 — common questions
What exactly does kisspeptin do that makes it so important?
It is the master upstream regulator of the reproductive axis. It stimulates GnRH neurons in the hypothalamus to release GnRH, which drives LH and FSH from the pituitary, which in turn drives testosterone, estrogen, spermatogenesis, and ovulation. People born with inactivating KISS1R mutations fail to enter puberty despite an otherwise intact axis — which is why exogenous kisspeptin can drive the whole cascade downstream.
How is KP-10 different from KP-54?
Both are endogenous kisspeptin peptides. KP-54 is the longer 54-amino-acid parent cleavage product; KP-10 is the C-terminal decapeptide that retains essentially all of the receptor activity. KP-10 has a shorter half-life (~4 min vs ~30 min for KP-54) but is functionally equivalent at KISS1R. KP-10 is the more common research-market form; clinical trials often use KP-54 where the longer half-life simplifies dosing, such as ovulation induction. Importantly, the strongest HSDD and IVF trial data were generated on KP-54, not KP-10.
Can I use KP-10 during an active anabolic or TRT cycle?
No — it will not work during active high-dose androgen administration. Exogenous androgens produce powerful negative feedback at both the hypothalamus and pituitary that overwhelms any upstream kisspeptin stimulation. KP-10 becomes useful during recovery phases (typically 2-4 weeks after androgens clear), not during active suppression. hCG, which acts directly at testicular LH receptors, is the appropriate on-cycle testicular support.
How quickly will I feel KP-10 working?
It depends on the goal. For axis recovery, effects are lab-measured over weeks — LH/FSH rise within days, testosterone follows over 2-4 weeks, and full normalization often takes 6-12 weeks, with libido and morning erections returning gradually. For central desire/HSDD effects, acute subjective changes in libido and emotional engagement often occur within 1-2 hours of dosing. The axis and limbic effects operate on different timescales.
Does KP-10 help with libido even if testosterone is normal?
Research suggests yes. Kisspeptin's effects on sexual desire and romantic processing operate through limbic regions (amygdala, hippocampus) that are pharmacologically separate from the HPG axis. Imperial College fMRI studies show enhanced sexual-arousal circuit activation from kisspeptin even in eugonadal men, and HSDD trials in women showed improvements in subjective desire not driven by hormone changes. Individual response varies.
Is KP-10 FDA approved?
No. Kisspeptin-10 has no FDA (or EMA) approval for any indication. It is used in clinical research and early-stage pharmaceutical development for fertility, HPG-axis disorders, and HSDD, currently at Phase 1/2, and will need Phase 3 data before any approval path. Research-grade KP-10 is sold for laboratory use only.
Will KP-10 make me fertile if I've been trying to conceive?
Possibly, for both sexes. In men with suppressed axes, kisspeptin-driven LH/FSH restoration can rebuild spermatogenesis over 3-6 months; in women with functional hypothalamic amenorrhea it can restore ovulation, and kisspeptin-triggered ovulation has produced live births in IVF cycles. However, it fixes upstream signaling only — it cannot compensate for primary gonadal failure or structural factors. Fertility work should be medically supervised.
Do I need to cycle KP-10?
Published human trials have not shown clear tachyphylaxis or axis desensitization with kisspeptin use up to several months. Still, conservative cycling (e.g., 4-8 weeks on, 2 weeks off) is reasonable given the lack of long-term safety data. Continuous daily high-dose use for many months is an uncharacterized regimen; most off-label users structure cycles around a specific goal rather than indefinite use.
